1 Lucchinetti CF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188-2197.
2 Banwell B, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72(3):232-239.
3 Huppke P, et al. Therapy of highly active pediatric multiple sclerosis. MSJ. 2019;25(1):72–80.
4 Renoux C, et al. Natural History of Multiple Sclerosis with Childhood Onset. N Engl J Med. 2007;356(25):2603-2613.
5 Amato MP, et al. Pediatric multiple sclerosis: Cognition and mood. Neurology. 2016;87(2):S82–S87.
6 Aubert-Broche B, et al. Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology. 2014;83:2140–2146.
7 Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet. 2018;391(10130):1622-1636.
8 O’Mahony J, et al. Recovery From Central Nervous System Acute Demyelination in Children Pediatrics. 2015 Jul;136(1):e115-23.
9 Giovannoni G, et al. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018,;Jun;31(3):233-243.
10 Ghezzi A, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015;15:174.
11 Chitnis T, et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N Engl J Med. 2018;379:1017-27.
12 Baroncini D, et al. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurol 2021;78(6):726-735.